Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 20;29(1):72.
doi: 10.1186/s40001-024-01660-7.

Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study

Dan Liu #  1 , Jian Zhao #  1 , Hui Xia #  1 , Shi Dong  1 , Songjuan Yan  1 , Yugang Zhuang  1 , Yuanzhuo Chen  2 , Hu Peng  3
Affiliations

Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study

Dan Liu et al. Eur J Med Res. .

Abstract

Purpose: The choice of continuous renal replacement therapy (CRRT) anticoagulation program for patients at high risk of bleeding has always been a complex problem in clinical practice. Clinical regimens include regional citrate anticoagulation (RCA) and nafamostat mesylate (NM). This study aimed to evaluate the efficacy and safety of these two anticoagulants for CRRT in patients at high risk of bleeding to guide their clinical use better.

Patients and methods: Between January 2021 and December 2022, 307 patients were screened for this study. Forty-six patients were finally enrolled: 22 in the regional citrate anticoagulation group and 24 in the nafamostat mesylate group. We collected patients' baseline characteristics, laboratory indicators before CRRT, and CRRT-related data. We then performed a statistical analysis of the data from both groups of patients.

Results: In our study, the baseline characteristics did not differ significantly between the two groups; the baseline laboratory indicators before CRRT of patients in the two groups were not significantly different. The duration of CRRT was 600 min in the regional citrate anticoagulation (RCA) group, 615 min in the nafamostat mesylate (NM) group; the success rate was 90.7% in the RCA group, and 85.6% in the NM group, the anticoagulant efficacy between the two groups was comparable. There was no significant difference in the safety of anticoagulation between the two groups. We used Generalized Estimating Equations (GEE) to test whether different anticoagulation methods significantly affected the success rate of CRRT and found no statistical difference between RCA and NM.

Conclusion: Our study suggests that nafamostat mesylate's anticoagulant efficacy and safety are not inferior to regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding.

Keywords: Anticoagulation; Continuous renal replacement therapy; High risk of bleeding; Nafamostat mesylate; Regional citrate anticoagulation.

PubMed Disclaimer

Conflict of interest statement

The authors report no competing interests in this work.

Figures

Fig. 1
Fig. 1
Enrollment strategy of the study
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Herten P-J, Vlieghe E, Bottieau E, et al. The emergence of travel-related infections in critical care units [J] J Trans Internal Med. 2022;10(4):328. doi: 10.2478/jtim-2022-0042. - DOI - PMC - PubMed
    1. Yang R, Chen X, Li S, et al. From critical care nephrology to critical care blood purification [J] J Trans Internal Med. 2021;9(1):4. doi: 10.2478/jtim-2021-0015. - DOI - PMC - PubMed
    1. van de Wetering J, Westendorp RG, van der Hoeven JG, et al. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage [J] J Am Soc Nephrol. 1996;7(1):145. doi: 10.1681/ASN.V71145. - DOI - PubMed
    1. MacEwen C, Watkinson P, Winearls C. Circuit life versus bleeding risk: the impact of achieved activated partial thromboplastin time versus achieved filtration fraction [J] Ther Apher Dial. 2015;19(3):259. doi: 10.1111/1744-9987.12253. - DOI - PubMed
    1. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury [J] Nephron Clin Pract. 2012;120(4):C179. doi: 10.1159/000339789. - DOI - PubMed

LinkOut - more resources